Drug
Pibrentasvir clinical trials
Also written ABT-530.
- studies test it
- 8
- open now
- 0
- in phase 3
- 3
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Glecaprevir (7) · Ribavirin (3) · Glecaprevir and pibrentasvir (2) · Paritaprevir (1) · Ritonavir (1)
Studies
Open first, then newest update. How each study uses pibrentasvir is read from its arms, and is right about nine times in ten.
Testing it · 8
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedPhase 2/3AbbVieNCT02243293Written as ABT-530
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 InfectionCompletedPhase 2AbbVieNCT02243280Written as ABT-530
- A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)CompletedPhase 2AbbVieNCT01995071Written as ABT-530
- A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530CompletedPhase 2/3AbbVieNCT02441283Written as ABT-530
- A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) InfectionCompletedPhase 2AbbVieNCT02068222Written as ABT-530
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedPhase 2/3AbbVieNCT02446717Written as ABT-493, ABT-530
- Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal FunctionCompletedPhase 1AbbVieNCT02442258Written as ABT-530
- Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic FunctionCompletedPhase 1AbbVieNCT02296905Written as ABT-530
Codes
What other systems call pibrentasvir · ClinicalTrials.gg INT000784
- MeSH (NLM) C000622691pibrentasvirOne source NLM
- UNII (FDA) 2WU922TK3LPIBRENTASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1940636Confirmed FDA, Wikidata
- Wikidata Q39048005pibrentasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166601PibrentasvirOne source FDA
- DrugBank DB13878One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622691 | pibrentasvir | One source NLM |
| UNII (FDA) | 2WU922TK3L | PIBRENTASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1940636 | — | Confirmed FDA, Wikidata |
| Wikidata | Q39048005 | pibrentasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166601 | Pibrentasvir | One source FDA |
| DrugBank | DB13878 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.